nafamostat has been researched along with Burns in 3 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Burns: Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The systemic effects of epidermal growth factor (EGF) ointment containing nafamostat (NM), gabexate, or gelatin was studied in rats with burns or open wounds." | 7.68 | Systemic effects of epidermal growth factor (EGF) ointment containing protease inhibitor or gelatin in rats with burns or open wounds. ( Fuwa, T; Iwakawa, S; Kiyohara, Y; Komada, F; Okumura, K, 1993) |
| "When epidermal growth factor (EGF) ointment containing a protease inhibitor, nafamostat (NM), was applied to burn sites in rats, the superoxide dismutase (SOD) enzyme activity and protein content increased 45% and 60%, respectively, at these sites 1 d after the burns compared with the control ointment." | 3.68 | Cytoprotective effects of epidermal growth factor (EGF) ointment containing nafamostat, a protease inhibitor, on tissue damage at burn sites in rats. ( Hirai, M; Iwakawa, S; Kiyohara, Y; Komada, F; Nishiguchi, K; Okumura, K, 1993) |
| "The systemic effects of epidermal growth factor (EGF) ointment containing nafamostat (NM), gabexate, or gelatin was studied in rats with burns or open wounds." | 3.68 | Systemic effects of epidermal growth factor (EGF) ointment containing protease inhibitor or gelatin in rats with burns or open wounds. ( Fuwa, T; Iwakawa, S; Kiyohara, Y; Komada, F; Okumura, K, 1993) |
| " No improvement in wound healing was found on topical application of EGF alone to burn sites, but an ointment containing EGF and nafamostat mesilate (NM), a protease inhibitor, accelerated the healing rate of burns." | 3.68 | Improvement in wound healing by epidermal growth factor (EGF) ointment. II. Effect of protease inhibitor, nafamostat, on stabilization and efficacy of EGF in burn. ( Fuwa, T; Hirai, M; Iwakawa, S; Kiyohara, Y; Komada, F; Okumura, K, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiyohara, Y | 3 |
| Nishiguchi, K | 1 |
| Komada, F | 3 |
| Iwakawa, S | 3 |
| Hirai, M | 2 |
| Okumura, K | 3 |
| Fuwa, T | 2 |
3 other studies available for nafamostat and Burns
| Article | Year |
|---|---|
Cytoprotective effects of epidermal growth factor (EGF) ointment containing nafamostat, a protease inhibitor, on tissue damage at burn sites in rats.
Topics: Animals; Benzamidines; Blotting, Northern; Burns; Drug Combinations; Epidermal Growth Factor; Guanid | 1993 |
Systemic effects of epidermal growth factor (EGF) ointment containing protease inhibitor or gelatin in rats with burns or open wounds.
Topics: Animals; Aspartate Aminotransferases; Benzamidines; Body Weight; Burns; Drug Interactions; Drug Syne | 1993 |
Improvement in wound healing by epidermal growth factor (EGF) ointment. II. Effect of protease inhibitor, nafamostat, on stabilization and efficacy of EGF in burn.
Topics: Animals; Benzamidines; Burns; Drug Interactions; Drug Stability; Drug Therapy, Combination; Epiderma | 1991 |